Overall, targeting mTOR signaling with sirolimus and blocking the PI3K pathway are both promising and established strategies to reduce acute and chronic GvHD either as prophylaxis or treatment of an established disease and may be preferred to other regimens for patients after allo-HCT. The gene discussed is MTOR; the disease is graft versus host disease.